Bayesian Meta-Experimental Design: Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes

Biometrics - United Kingdom
doi 10.1111/j.1541-0420.2011.01679.x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Cardiovascular Risk Factor Burden in U.S. People With Incident Type 2 Diabetes Receiving Antidiabetic and Cardioprotective Therapies

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2019English

Type 2 Diabetes and Cardiovascular Risk Factors

Current Medical Research and Opinion
Medicine
2011English

Cardiovascular Risk in Patients With Type 2 Diabetes

CMAJ
Medicine
2005English

Management of Cardiovascular Risk Factors With Pioglitazone Combination Therapies in Type 2 Diabetes: An Observational Cohort Study

Cardiovascular Diabetology
Internal MedicineCardiologyEndocrinologyCardiovascular MedicineMetabolismDiabetes
2011English

Glucose-Lowering Therapies for Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: State-Of-The-Art Review

Mayo Clinic Proceedings
Medicine
2018English

Cardiologists' Approach to Managing Cardiovascular Risk in Patients With Type 2 Diabetes

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

FDA Guidance on Cardiovascular Risk of Antidiabetic Therapies: One Decade Later

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Cardiovascular Effects of Incretin-Based Therapies in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

The Lancet Diabetes and Endocrinology
Internal MedicineEndocrinologyMetabolismDiabetes
2016English

Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk

Journal of Managed Care Pharmacy
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy